Familial Lipoprotein Lipase Deficiency
Synonym: Familial LPL Deficiency
John R Burnett, MB ChB, MD, PhD, FRCPA, Amanda J Hooper, PhD, and Robert A Hegele, MD, FRCPC, FACP.
Author Information and AffiliationsInitial Posting: October 12, 1999; Last Update: June 22, 2017.
Estimated reading time: 18 minutes
Summary
Clinical characteristics.
Familial lipoprotein lipase (LPL) deficiency usually presents in childhood and is characterized by very severe hypertriglyceridemia with episodes of abdominal pain, recurrent acute pancreatitis, eruptive cutaneous xanthomata, and hepatosplenomegaly. Clearance of chylomicrons from the plasma is impaired, causing triglycerides to accumulate in plasma and the plasma to have a milky (lactescent or lipemic) appearance. Symptoms usually resolve with restriction of total dietary fat to ≤20 g/day.
Management.
Treatment of manifestations: Treatment is based on medical nutrition therapy to maintain plasma triglyceride concentration below 1000 mg/dL. Maintenance of triglyceride levels below 2000 mg/dL prevents recurrent abdominal pain. Restriction of dietary fat to ≤20 g/day or 15% of a total energy intake is usually sufficient to reduce plasma triglyceride concentration and to keep the individual with familial LPL deficiency free of symptoms. An acute pancreatitis episode is treated with standard care.
Prevention of secondary complications: Prevention of recurrent acute pancreatitis decreases the risk of developing diabetes mellitus.
Surveillance: Monitoring of plasma triglycerides.
Agents/circumstances to avoid: Agents known to increase endogenous triglyceride concentration such as alcohol, oral estrogens, diuretics, isotretinoin, glucocorticoids, selective serotonin reuptake inhibitors, and beta-adrenergic blocking agents; fish oil supplements are contraindicated because they contribute to chylomicron levels.
Pregnancy management: For pregnant women with LPL deficiency, extreme dietary fat restriction to <2 g/day during the second and third trimesters of pregnancy with close monitoring of plasma triglyceride concentration is recommended.
Other: The lipid-lowering drugs that are used to treat other disorders of lipid metabolism are not effective in individuals with familial LPL deficiency.
Genetic counseling.
Familial LPL deficiency is inherited in an autosomal recessive manner. Each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the pathogenic variants in the family are known.
Diagnosis
Suggestive Findings
Familial lipoprotein lipase (LPL) deficiency should be suspected in individuals (particularly those age <40 years) with the following clinical and supportive laboratory findings.
Clinical findings
Supportive laboratory findings
Impaired clearance of chylomicrons from plasma causing the plasma to have a milky (lactescent or lipemic) appearance
Plasma triglyceride concentrations greater than 2000 mg/dL in the untreated state, regardless of fasting status
Establishing the Diagnosis
The diagnosis of LPL deficiency is established in a proband by the identification of biallelic pathogenic variants in LPL on molecular genetic testing (see Table 1).
A consensus diagnostic algorithm has been published [Stroes et al 2017] (see Figure 3).
Molecular genetic testing approaches can include single-gene testing or use of a multigene panel:
A multigene panel that includes
LPL and other genes of interest for the chylomicronemia syndrome (see
Differential Diagnosis) may also be considered. Note: (1) The genes included in the panel and the diagnostic
sensitivity of the testing used for each
gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this
GeneReview; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition while limiting identification of variants of
uncertain significance and pathogenic variants in genes that do not explain the underlying
phenotype. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused
exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include
sequence analysis,
deletion/duplication analysis, and/or other non-sequencing-based tests.
For an introduction to multigene panels click
here. More detailed information for clinicians ordering genetic tests can be found
here.
Table 1.
Molecular Genetic Testing Used in Familial Lipoprotein Lipase Deficiency
View in own window
| Gene 1 | Method | Proportion of Probands with Pathogenic Variants 2 Detectable by Method |
|---|
|
LPL
| Sequence analysis 3 | ~97% 4 |
| Gene-targeted deletion/duplication analysis 5 | ~3% 6 |
- 1.
- 2.
- 3.
- 4.
- 5.
Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.
- 6.
Measurement of lipoprotein lipase enzyme activity. Affected individuals have low or absent LPL enzyme activity in an assay system that contains either normal plasma or apolipoprotein C-II (apoC-II; a cofactor of LPL) and excludes hepatic lipase (HL). This assay is not routinely available and is generally only performed at specialist centers.
Clinical Characteristics
Clinical Description
Familial lipoprotein lipase (LPL) deficiency usually presents in childhood with episodes of abdominal pain, recurrent acute pancreatitis, eruptive cutaneous xanthomata, and hepatosplenomegaly. Males and females are affected equally.
Approximately 25% of affected children develop symptoms before age one year and the majority develop symptoms before age ten years; however, some individuals present for the first time during pregnancy. The severity of symptoms correlates with the degree of chylomicronemia. Chylomicrons are large triglyceride-rich lipoprotein particles that appear in the circulation shortly after the ingestion of dietary fat; normally, they are cleared from plasma after an overnight fast. The degree of chylomicronemia in LPL deficiency varies by dietary fat intake.
The abdominal pain, which can vary from mildly bothersome to incapacitating, is usually mid-epigastric with radiation to the back. It may be diffuse and mimic an acute abdomen, often leading to unnecessary abdominal exploratory surgery. The pain probably results from chylomicronemia leading to pancreatitis.
Kawashiri et al [2005] reported that individuals with LPL deficiency can lead a fairly normal life on a diet very low in total fat content. The secondary complications of pancreatitis – diabetes mellitus, steatorrhea, and pancreatic calcification – are unusual in individuals with familial LPL deficiency and rarely occur before middle age. Pancreatitis in LPL deficiency may rarely be associated with total pancreatic necrosis and death.
About 50% of individuals with familial LPL deficiency have eruptive xanthomas, small yellow papules localized over the trunk, buttocks, knees, and extensor surfaces of the arms. Xanthomas are deposits of lipid in the skin that result from the extravascular phagocytosis of chylomicrons by macrophages. They can appear rapidly when plasma triglyceride concentration exceeds 2000 mg/dL and can sometimes regress if plasma triglyceride is normalized.
Xanthomas may become generalized. As a single lesion, they may be several millimeters in diameter; rarely, they may coalesce into plaques. They are usually not tender unless they occur at a site susceptible to repeated abrasion.
Hepatomegaly and splenomegaly often occur when plasma triglyceride concentrations are markedly increased. The organomegaly results from triglyceride uptake by macrophages, which become foam cells.
When triglyceride concentrations exceed 4000 mg/dL, the retinal arterioles and venules, and often the fundus itself, develop a pale pink color ("lipemia retinalis"), caused by light scattering by large chylomicrons. This coloration is reversible and vision is not affected.
Reversible neuropsychiatric findings, including mild dementia, depression, and memory loss, have also been reported with chylomicronemia [Heilman & Fisher 1974, Chait et al 1981].
Genotype-Phenotype Correlations
As most pathogenic LPL variants have been reported in individual case reports or small case series, reliable systematic correlation of genotype-phenotype relationships is challenging. There are no known genotype-phenotype correlations.
Nomenclature
Familial LPL deficiency is the most common form of the familial chylomicronemia syndrome, which was formerly known as "type 1 hyperlipoproteinemia."
Prevalence
The prevalence of familial LPL deficiency is approximately one in 1,000,000 in the general US population.
The disease has been described in all races. The prevalence is much higher in some areas of Quebec, Canada as a result of a founder effect.
Consanguinity is observed in some families with familial LPL deficiency caused by homozygous pathogenic LPL variants.
Differential Diagnosis
Familial lipoprotein lipase (LPL) deficiency should be considered in young persons with the chylomicronemia syndrome, defined as abdominal pain, eruptive xanthomata, plasma triglyceride concentrations greater than 2000 mg/dL, and fasting lipemic plasma. However, the majority of individuals with chylomicronemia and plasma triglyceride concentration greater than 2000 mg/dL do not have familial LPL deficiency; rather, they have one of the more common genetic disorders of triglyceride metabolism (i.e., familial combined hyperlipidemia and monogenic familial hypertriglyceridemia). Hypertriglyceridemia can also be polygenic, due to both heterozygous rare large-effect variants and accumulations of common rare small-effect variants in several genes and loci [Hegele et al 2014]. With such genetic predisposition, clinical expression of chylomicronemia typically requires the presence of secondary, non-genetic factors [Brunzell & Deeb 2001].
Secondary causes of hypertriglyceridemia include: diabetes mellitus; paraproteinemia and lymphoproliferative disorders; use of alcohol; and therapy with estrogen, glucocorticoids, selective serotonin reuptake inhibitors, atypical antipsychotic agents, isotretinoin, or certain antihypertensive agents. In one series of 123 individuals evaluated for marked hypertriglyceridemia, 110 had an acquired cause of hypertriglyceridemia combined with a common genetic form of hypertriglyceridemia, five had familial LPL deficiency, five had other rare genetic forms of hypertriglyceridemia, and three had an unknown cause [Chait & Brunzell 1983].
Other than LPL deficiency, the chylomicronemia syndrome may be caused by biallelic pathogenic variants in apolipoprotein C-II (APOC2), apolipoprotein A-V (APOA5), lipase maturation factor 1 (LMF1) or GPIHBP1 (see Table 2).
Table 2.
Genetic Causes of Primary Monogenic Chylomicronemia
View in own window
| Gene (Gene Product) | Homozygote Prevalence | Gene Product Function | Clinical Features | Molecular Features | % of Monogenic Variants | References |
|---|
LPL
(LPL) | ~1 per million individuals 1 | Hydrolysis of triglycerides & peripheral uptake of FFA | Severe chylomicronemia in infancy or childhood | Severely reduced or absent LPL enzyme activity | 95.0 | Murthy et al [1996], Jap et al [2003], Gotoda et al [2012], Martín-Campos et al [2014] |
| APOC2 (apoC-II) | 10 families reported | Required cofactor of LPL | Severe chylomicronemia in childhood or adolescence | Absent or nonfunctional apoC-II | 2.0 | Gotoda et al [2012], Okubo et al [2015] |
| GPIHBP1 (GPI-HBP1) | 10 families reported | Stabilizes binding of chylomicrons near LPL; supports lipolysis | Chylomicronemia in late adulthood | Absent or defective GPI-HBP1 | 2.0 | Beigneux et al 2009, Gin et al [2012] |
| APOA5 (apoA-V) | Three families reported | Enhancer of LPL activity | Chylomicronemia in late adulthood | Absent or defective apoA-V | 0.6 | Calandra et al [2006], Nilsson et al [2011] |
| LMF1 (LMF1) | Two families reported | Chaperone molecule required for proper LPL folding and/or expression | Chylomicronemia in late adulthood | Absent or defective LMF1 | 0.4 |
Péterfy [2012]
|
apoA-V = apolipoprotein A-V; apoC-II = apolipoprotein C-II; FFA = free fatty acid; GPI-HBP1 = glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1; LMF1 = lipase maturation factor 1; LPL = lipoprotein lipase
- 1.
Familial apolipoprotein C-II (apoC-II) deficiency (OMIM
207750). ApoC-II is a cofactor for LPL. Familial apoC-II deficiency is an extremely rare
autosomal recessive disorder that differs from
familial LPL deficiency in that (1) symptoms generally develop at a later age (13-60 years) and (2) individuals may develop chronic pancreatic insufficiency with steatorrhea and insulin-dependent diabetes mellitus. The diagnosis is based on the identification of
biallelic pathogenic variants in
APOC2, on assay of plasma apoC-II concentration or activation of a purified LPL standard, and on gel electrophoresis of VLDL apolipoproteins. Infusion of normal plasma into an individual with familial apoC-II deficiency results in dramatic reduction of the plasma triglyceride concentration. Treatment is a low-fat diet throughout life.
Familial apolipoprotein A-V deficiency (OMIM
144650). It has been suggested that apoA-V facilitates the interaction of endothelial heparan sulfate with apoC-II on triglyceride-rich lipoproteins and the interaction of apoC-II with LPL on the vascular endothelium. Several families with apoA-V deficiency have been reported to have severe hypertriglyceridemia. Biallelic large-effect
loss-of-function pathogenic variants in
APOA5 can lead to
familial chylomicronemia syndrome, while
heterozygous carriers are predisposed to hypertriglyceridemia, but often demonstrate a normal clinical and biochemical
phenotype in the absence of secondary non-genetic factors.
Familial lipase maturation factor 1 (LMF1) deficiency (OMIM
246650). LMF1 is a transmembrane protein localized to the endoplasmic reticulum involved in the maturation of both LPL and hepatic lipase (HL). One affected individual,
homozygous for a
biallelic LMF1 pathogenic variant, had very low LPL activity, modestly low HL activity, and chylomicronemia [
Péterfy et al 2007].
Familial glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1) deficiency (OMIM
615947). GPIHBP1 appears to be a binding site for LPL on the capillary endothelial surface, perhaps through binding with apoA-V [
Beigneux et al 2007]. Several individuals with GPIHBP1 deficiency have been described. Biallelic large-effect
loss-of-function variants of
GPIHBP1 can lead to
familial chylomicronemia syndrome, while
heterozygous carriers are predisposed to hypertriglyceridemia, but often demonstrate a normal clinical and biochemical
phenotype in the absence of secondary non-genetic factors. Recently, autoantibodies against GPIHBP1 were shown to cause chylomicronemia syndrome [
Beigneux et al 2017].
Management
Evaluations Following Initial Diagnosis
To establish the extent of disease and needs in an individual diagnosed with familial lipoprotein lipase (LPL) deficiency, measurement of plasma triglyceride concentration is recommended.
Consultation with a clinical geneticist and/or genetic counselor may also be considered.
Treatment of Manifestations
Medical nutrition therapy. Morbidity and mortality can be prevented by maintaining plasma triglyceride concentration at less than 2000 mg/dL; a good clinical goal is less than 1000 mg/dL [Viljoen & Wierzbicki 2012]. Restriction of dietary fat to no more than 20 g/day or 15% of total energy intake is usually sufficient to reduce plasma triglyceride concentration and to keep the individual with familial LPL deficiency free of symptoms.
Medium-chain triglycerides may be used for cooking, as they are absorbed directly into the portal vein without becoming incorporated into chylomicron triglyceride.
The success of therapy depends on the individual's acceptance of the fat restriction, including both unsaturated and saturated fat. Note: Fish oil supplements, which are effective in disorders of excess hepatic triglyceride production, are not effective in LPL deficiency and are contraindicated (see Agents/Circumstances to Avoid).
The enlarged liver and spleen can return to normal size within one week of lowering of triglyceride concentrations.
The xanthomas can clear over the course of weeks to months. Recurrent or persistent eruptive xanthomas indicate inadequate therapy.
Pancreatitis associated with the chylomicronemia syndrome is treated in the manner typical for other forms of pancreatitis.
Discontinuation of oral fat intake stops chylomicron triglyceride formation, and replacement with hypocaloric parenteral nutrition decreases VLDL triglyceride production.
Administration of excess calories, as in hyperalimentation, is contraindicated in the acute state. The intravenous administration of lipid emulsions may lead to persistent or recurrent pancreatitis.
If recurrent pancreatitis with severe hypertriglyceridemia occurs, total dietary fat intake needs to be reduced.
Prevention of Secondary Complications
Prevention of recurrent acute pancreatitis decreases the risk of developing diabetes mellitus. Fat malabsorption is very rare.
Surveillance
Plasma triglyceride levels need to be followed over time to evaluate the affected individual’s success in following the very low-fat dietary recommendations. When the triglyceride level is above 1000 mg/dL, a fasting sample is not required for this evaluation. Other components of the lipid profile do not need to be routinely measured.
Affected individuals who develop abdominal pain need to contact their physician.
Agents/Circumstances to Avoid
Avoidance of agents known to increase endogenous triglyceride concentration such as alcohol, oral estrogens, diuretics, isotretinoin, glucocorticoids, selective serotonin reuptake inhibitors, and beta-adrenergic blocking agents is recommended.
Fish oil supplements are contraindicated as they contribute to chylomicron levels.
Evaluation of Relatives at Risk
It is appropriate to evaluate at-risk sibs during infancy. Early diagnosis and implementation of dietary fat intake restriction can prevent symptoms and related medical complications.
Evaluations can include:
See Genetic Counseling for issues related to evaluation of at-risk relatives for genetic counseling purposes.
Pregnancy Management
During pregnancy in a woman with LPL deficiency, extreme dietary fat restriction to less than two grams per day during the second and third trimester with close monitoring of plasma triglyceride concentration can result in delivery of a normal infant with normal plasma concentrations of essential fatty acids [Al-Shali et al 2002].
One woman with LPL deficiency delivered a normal child following a one-gram per day fat diet and treatment with gemfibrozil (600 mg/day) [Tsai et al 2004]. Despite concerns about the possibility of essential fatty acid deficiency in the newborn, normal essential fatty acids were found in cord blood, as were normal levels of fibrate metabolites.
See MotherToBaby for further information on medication use during pregnancy.
Therapies Under Investigation
LPL gene therapy is available in Europe and the US for the treatment of familial LPL deficiency. It consists of the LPL Ser447Ter variant in an adeno-associated virus serotype 1 (alipogene tiparvovec). Twenty percent of the general population has the Ser447Ter allelic variant, which results in a prematurely truncated LPL that is associated with increased lipolytic function and an anti-atherogenic lipid profile and can therefore be regarded as a naturally occurring gain-of-function variant (reviewed by Gaudet et al [2013]). Note that the standard nomenclature for this variant is NP_000228.1:p.Ser474Ter (NM_000237.2:c.1421C>G). Several other targeted therapies are in development or under investigation, including inhibitors of microsomal triglyceride transfer protein (MTP) [Sacks et al 2014], diacylglycerol acyl transferase 1 (DGAT1) [Meyers et al 2015], apoC-III [Gaudet et al 2014], and angiopoietin-like protein 3 (ANGPTL3) [Gryn & Hegele 2015].
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions.
Other
The lipid-lowering drugs that are used to treat other disorders of lipid metabolism are not effective in individuals with familial LPL deficiency.
Although plasmapheresis and antioxidant therapy have been suggested as treatment for pancreatitis, they do not appear to be needed for either acute therapy or long-term care.
Genetic Counseling
Genetic counseling is the process of providing individuals and families with
information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members; it is not meant to address all personal, cultural, or
ethical issues that may arise or to substitute for consultation with a genetics
professional. —ED.
Carrier Detection
Carrier testing for at-risk relatives requires prior identification of the LPL pathogenic variants in the family. The lipid phenotype of heterozygotes varies widely from completely normal to moderate-to-severe hypertriglyceridemia and cannot be used to predict carrier status.
Prenatal Testing and Preimplantation Genetic Testing
Once the LPL pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing for familial LPL deficiency are possible.
Differences in perspective may exist among medical professionals and in families regarding the use of prenatal testing. While most centers would consider use of prenatal testing to be a personal decision, discussion of these issues may be helpful. In practice, prenatal testing is rarely requested because of the availability of effective treatment.
Resources
GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click here.
Molecular Genetics
Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —ED.
Table A.
Familial Lipoprotein Lipase Deficiency: Genes and Databases
View in own window
Data are compiled from the following standard references: gene from
HGNC;
chromosome locus from
OMIM;
protein from UniProt.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
here.
Gene structure.
LPL comprises ten exons; the last one encodes the long untranslated 3’-end of the mRNA (NM_000237.2). The sequence of LPL is highly conserved among mammalian species.
Pathogenic variants. More than 220 pathogenic variants have been identified [Brunzell & Deeb 2001, Gilbert et al 2001]; see Table A, HGMD. Approximately 70% of these variants are missense, 10% nonsense, and 18% nucleotide insertions and deletions; a few splice site variants are also known. About 3% of pathogenic variants have an exon or multiexon deletion, duplication, insertion, or complex rearrangement.
Normal gene product. Lipoprotein lipase (LPL) is a glycoprotein that is synthesized in adipose tissue and cardiac and skeletal muscle, but not in the postpartum liver. It is transported to the luminal surface of the capillary endothelium of extrahepatic tissues. It is essential for the hydrolysis of chylomicron and VLDL triglycerides to provide free fatty acids to tissue for energy production. LPL has two major domains: a larger NH2-terminal domain linked by a short region to a COOH-terminal domain of approximately half its size. The globular NH2-terminal domain specifies the catalytic properties of the lipase, whereas the COOH-terminal domain specifies substrate specificity and heparin-binding properties. LPL encodes a protein of 475 amino acids that becomes a mature protein of 448 residues after cleavage of a signal peptide (NP_000228.1).
Abnormal gene product. Pathogenic deletions and nonsense and splice site variants presumably lead to absent or truncated LPL with defective catalytic activity. Most of the variants are in the highly conserved central homology region [Brunzell & Deeb 2001, Gilbert et al 2001]. Many missense variants result in LPL deficiency secondary to LPL homodimer instability.
References
Literature Cited
Al-Shali K, Wang J, Fellows F, Huff MW, Wolfe BM, Hegele RA. Successful pregnancy outcome in a patient with severe chylomicronemia due to compound heterozygosity for mutant lipoprotein lipase.
Clin Biochem. 2002;35:125–30. [
PubMed: 11983347]
Beigneux AP, Davies BS, Gin P, Weinstein MM, Farber E, Qiao X, Peale F, Bunting S, Walzem RL, Wong JS, Blaner WS, Ding ZM, Melford K, Wongsiriroj N, Shu X, de Sauvage F, Ryan RO, Fong LG, Bensadoun A, Young SG. Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons.
Cell Metab. 2007;5:279–91. [
PMC free article: PMC1913910] [
PubMed: 17403372]
Beigneux AP, Franssen R, Bensadoun A, Gin P, Melford K, Peter J, Walzem RL, Weinstein MM, Davies BS, Kuivenhoven JA, Kastelein JJ, Fong LG, Dallinga-Thie GM, Young SG. Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase.
Arterioscler Thromb Vasc Biol. 2009;29:956–62. [
PMC free article: PMC2811263] [
PubMed: 19304573]
Beigneux AP, Miyashita K, Ploug M, Blom DJ, Ai M, Linton MF, Khovidhunkit W, Dufour R, Garg A, McMahon MA, Pullinger CR, Sandoval NP, Hu X, Allan CM, Larsson M, Machida T, Murakami M, Reue K, Tontonoz P, Goldberg IJ, Moulin P, Charrière S, Fong LG, Nakajima K, Young SG. Autoantibodies against GPIHBP1 as a cause of hypertriglyceridemia.
N Engl J Med. 2017;376:1647–58. [
PMC free article: PMC5555413] [
PubMed: 28402248]
Brahm AJ, Hegele RA. Chylomicronaemia–current diagnosis and future therapies.
Nat Rev Endocrinol. 2015;11:352–62. [
PubMed: 25732519]
Brunzell JD, Deeb SS. Familial lipoprotein lipase deficiency, apo CII deficiency and hepatic lipase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8 ed. New York, NY: McGraw-Hill; 2001:2789-816.
Calandra S, Priore Oliva C, Tarugi P, Bertolini S. APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency.
Curr. Opin. Lipidol. 2006;17:122–7. [
PubMed: 16531747]
Chait A, Brunzell JD. Severe hypertriglyceridemia: role of familial and acquired disorders.
Metabolism. 1983;32:209–14. [
PubMed: 6827992]
Chait A, Robertson HT, Brunzell JD. Chylomicronemia syndrome in diabetes mellitus.
Diabetes Care. 1981;4:343–8. [
PubMed: 7344882]
Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG, Geary RS, Baker BF, Graham MJ, Crooke RM, Witztum JL. Targeting APOC3 in the familial chylomicronemia syndrome.
N Engl J Med. 2014;371:2200–6. [
PubMed: 25470695]
Gaudet D, Méthot J, Déry S, Brisson D, Essiembre C, Tremblay G, Tremblay K, de Wal J, Twisk J, van den Bulk N, Sier-Ferreira V, van Deventer S. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial.
Gene Ther. 2013;20:361–9. [
PMC free article: PMC4956470] [
PubMed: 22717743]
Gilbert B, Rouis M, Griglio S, de Lumley L, Laplaud P, Gilbert B, Rouis M, Griglio S, de Lumley L, Laplaud P. Lipoprotein lipase (LPL) deficiency: a new patient homozygote for the preponderant mutation Gly188Glu in the human LPL gene and review of reported mutations: 75% are clustered in exons 5 and 6.
Ann Genet. 2001;44:25–32. [
PubMed: 11334614]
Gin P, Goulbourne CN, Adeyo O, Beigneux AP, Davies BS, Tat S, Voss CV, Bensadoun A, Fong LG, Young SG. Chylomicronemia mutations yield new insights into interactions between lipoprotein lipase and GPIHBP1.
Hum Mol Genet. 2012;21:2961–72. [
PMC free article: PMC3373243] [
PubMed: 22493000]
Gotoda T, Shirai K, Ohta T, Kobayashi J, Yokoyama S, Oikawa S, Bujo H, Ishibashi S, Arai H, Yamashita S, Harada-Shiba M, Eto M, Hayashi T, Sone H, Suzuki H, Yamada N, et al. Diagnosis and management of type I and type V hyperlipoproteinemia.
J Atheroscler Thromb. 2012;19:1–12. [
PubMed: 22129523]
Gryn SE, Hegele RA. Novel therapeutics in hypertriglyceridemia.
Curr Opin Lipidol. 2015;26:484–91. [
PubMed: 26780002]
Hegele RA, Ginsberg HN, Chapman MJ, Nordestgaard BG, Kuivenhoven JA, Averna M, Borén J, Bruckert E, Catapano AL, Descamps OS, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Raal FJ, Ray KK, Santos RD, Stalenhoef AF, Stroes E, Taskinen MR, Tybjærg-Hansen A, Watts GF, Wiklund O, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.
Lancet Diabetes Endocrinol. 2014;2014;2:655–66. [
PMC free article: PMC4201123] [
PubMed: 24731657]
Heilman KM, Fisher WR. Hyperlipidemic dementia.
Arch Neurol. 1974;31:67–8. [
PubMed: 4834546]
Jap TS, Jenq SF, Wu YC, Chiu CY, Cheng HM. Mutations in the lipoprotein lipase gene as a cause of hypertriglyceridemia and pancreatitis in Taiwan.
Pancreas. 2003;27:122–6. [
PubMed: 12883259]
Kawashiri MA, Higashikata T, Mizuno M, Takata M, Katsuda S, Miwa K, Nozue T, Nohara A, Inazu A, Kobayashi J, Koizumi J, Mabuchi H. Long-term course of lipoprotein lipase (LPL) deficiency due to homozygous LPL(Arita) in a patient with recurrent pancreatitis, retained glucose tolerance, and atherosclerosis.
J Clin Endocrinol Metab. 2005;90:6541–4. [
PubMed: 16174715]
Martín-Campos JM, Julve J, Roig R, Martínez S, Errico TL, Martínez-Couselo S, Escolà-Gil JC, Méndez-González J, Blanco-Vaca F. Molecular analysis of chylomicronemia in a clinical laboratory setting: diagnosis of 13 cases of lipoprotein lipase deficiency.
Clin Chim Acta. 2014;429:61–8. [
PubMed: 24291057]
Meyers CD, Tremblay K, Amer A, Chen J, Jiang L, Gaudet D. Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome.
Lipids Health Dis. 2015;14:8. [
PMC free article: PMC4337059] [
PubMed: 25889044]
Murthy V, Julien P, Gagne C. Molecular pathobiology of the human lipoprotein lipase gene.
Pharmacol Ther. 1996;70:101–35. [
PubMed: 8843465]
Nilsson SK, Heeren J, Olivecrona G, Merkel M. Apolipoprotein A-V; a potent triglyceride reducer.
Atherosclerosis. 2011;219:15–21. [
PubMed: 21831376]
Okubo M, Toromanovic A, Ebara T, Murase T. Apolipoprotein C-II: a novel large deletion in APOC2 caused by Alu–Alu homologous recombination in an infant with apolipoprotein C-II deficiency.
Clin Chim Acta. 2015;438:148–53. [
PubMed: 25172036]
Péterfy M, Ben-Zeev O, Mao HZ, Weissglas-Volkov D, Aouizerat BE, Pullinger CR, Frost PH, Kane JP, Malloy MJ, Reue K, Pajukanta P, Doolittle MH. Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia.
Nat Genet. 2007;39:1483–7. [
PubMed: 17994020]
Sacks FM, Stanesa M, Hegele RA. Severe hypertriglyceridemia with pancreatitis: thirteen years' treatment with lomitapide.
JAMA Intern Med. 2014;174:443–7. [
PubMed: 24366202]
Stroes E, Moulin P, Parhofer KG, Rebours V, Lӧhr JM, Averna M. Diagnostic algorithm for familial chylomicronemia syndrome.
Atheroscler Suppl. 2017;23:1–7. [
PubMed: 27998715]
Tsai EC, Brown JA, Veldee MY, Anderson GJ, Chait A, Brunzell JD. Potential of essential fatty acid deficiency with extremely low fat diet in lipoprotein lipase deficiency during pregnancy: A case report.
BMC Pregnancy Childbirth. 2004;4:27. [
PMC free article: PMC544881] [
PubMed: 15610556]
Viljoen A, Wierzbicki AS. Diagnosis and treatment of severe hypertriglyceridemia.
Expert Rev Cardiovasc Ther. 2012;10:505–14. [
PubMed: 22458582]
Chapter Notes
Author History
John D Brunzell, MD; University of Washington (1999-2017)
John R Burnett, MB ChB, MD, PhD, FRCPA (2017-present)
Robert A Hegele, MD, FRCPC, FACP (2017-present)
Amanda J Hooper, PhD (2017-present)
Revision History
22 June 2017 (ma) Comprehensive update posted live
15 December 2011 (me) Comprehensive update posted live
28 July 2009 (me) Comprehensive update posted live
24 April 2006 (me) Comprehensive update posted live
9 April 2004 (me) Comprehensive update posted live
18 February 2002 (me) Comprehensive update posted live
12 October 1999 (me) Review posted live
April 1999 (jb) Original submission
